Introduction Ramucirumab (RAM) plus erlotinib was found to have superior progression-free
survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC …

Introduction The phase 3 RELAY global study (NCT02411448) revealed significant
improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM+ …

RELAY (NCT02411448) showed a superior progression free survival benefit with RAM+
ERL versus (v) PBO+ ERL (mPFS 19.4 vs 12.4 mo, HR 0.59, p-value< 0.0001). We …

Introduction EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo
(PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for …

9564 Background: The phase III randomized part of the RELAY study (Part B; RELAY;
NCT02411448) showed a significant improvement in progression-free survival (PFS) for …

Background In EGFR mutated, metastatic (met) NSCLC, outcomes from EGFR tyrosine
kinase inhibitors (TKIs) have differed historically by mutation (mut) type present, with lower …

In the global phase III RELAY study, ramucirumab plus erlotinib (RAM+ ERL) demonstrated
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …

Objective In the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior
progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated …

Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …

Background RELAY is a randomized, double-blind phase 1b/3 study investigating the
efficacy and safety of the addition of ramucirumab (a human IgG1 monoclonal antibody that …